This viewpoint highlights advances in MCHR1 antagonists improving efficacy in obesity, suggesting potential clinical benefits.
For more than two decades, MCHR1 antagonists have been extensively investigated, but clinical progress has been hindered by toxicity and inadequate brain exposure. This Viewpoint highlights recent advances that have enabled the discovery of a novel MCHR1 antagonist with improved brain penetration and reduced toxicity, allowing it to advance into clinical trials.
No takes yet. Share an insight, caveat, or question.
David R. Luthin (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: